• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Murphy Canyon Acquisition Corp.

    10/2/23 4:30:17 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MURF alert in real time by email
    SC 13G 1 ea186168-13gnirland_con.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Conduit Pharmaceuticals Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

     

    20678X106

    (CUSIP Number)

     

    September 22, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    SCHEDULE 13G

    CUSIP No. 20678X106

     

    1

    Names of Reporting Persons

     

    Nirland Limited

    2

    Check the appropriate box if a member of a Group (see instructions)
    (a) ☐

    (b) ☐

    3

    Sec Use Only

     

    4

    Citizenship or Place of Organization

     

    Guernsey

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With: 
    5

    Sole Voting Power

     

    -0-

    6

    Shared Voting Power

     

    6,520,311 (1)(2)

    7

    Sole Dispositive Power

     

    -0-

    8

    Shared Dispositive Power

     

    6,520,311 (1)(2)

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,520,311 (1)(2)

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    ☐

    11

    Percent of class represented by amount in row (9)

     

    8.8% (1)(3)

    12

    Type of Reporting Person (See Instructions)

     

    CO

     

    2

     

     

    SCHEDULE 13G

    CUSIP No. 20678X106

     

    1

    Names of Reporting Persons

     

    Stockton Limited

    2

    Check the appropriate box if a member of a Group (see instructions)
    (a) ☐

    (b) ☐

    3

    Sec Use Only

     

    4

    Citizenship or Place of Organization

     

    Guernsey

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With: 
    5

    Sole Voting Power

     

    -0-

    6

    Shared Voting Power

     

    6,520,311 (1)(2)

    7

    Sole Dispositive Power

     

    -0-

    8

    Shared Dispositive Power

     

    6,520,311 (1)(2)

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,520,311 (1)(2)

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    ☐

    11

    Percent of class represented by amount in row (9)

     

    8.8% (1)(3)

    12

    Type of Reporting Person (See Instructions)

     

    CO

     

    3

     

     

    SCHEDULE 13G

    CUSIP No. 20678X106

     

    1

    Names of Reporting Persons

     

    The Rowland Master Trust

    2

    Check the appropriate box if a member of a Group (see instructions)
    (a) ☐

    (b) ☐

    3

    Sec Use Only

     

    4

    Citizenship or Place of Organization

     

    Guernsey

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With: 
    5

    Sole Voting Power

     

    -0-

    6

    Shared Voting Power

     

    6,520,311 (1)(2)

    7

    Sole Dispositive Power

     

    -0-

    8

    Shared Dispositive Power

     

    6,520,311 (1)(2)

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,520,311 (1)(2)

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    ☐

    11

    Percent of class represented by amount in row (9)

     

    8.8% (1)(3)

    12

    Type of Reporting Person (See Instructions)

     

    OO

     

    4

     

     

    SCHEDULE 13G

    CUSIP No. 20678X106

     

    1

    Names of Reporting Persons

     

    Dovet Limited

    2

    Check the appropriate box if a member of a Group (see instructions)
    (a) ☐

    (b) ☐

    3

    Sec Use Only

     

    4

    Citizenship or Place of Organization

     

    Guernsey

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With: 
    5

    Sole Voting Power

     

    -0-

    6

    Shared Voting Power

     

    6,520,311 (1)(2)

    7

    Sole Dispositive Power

     

    -0-

    8

    Shared Dispositive Power

     

    6,520,311 (1)(2)

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,520,311 (1)(2)

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    ☐

    11

    Percent of class represented by amount in row (9)

     

    8.8% (1)(3)

    12

    Type of Reporting Person (See Instructions)

     

    CO

     

    (1)Includes (i) 2,000,000 shares of common stock, par value $0.0001 per share (the “Common Stock”) of Conduit Pharmaceuticals Inc., formerly Murphy Canyon Acquisition Corp. (the “Issuer”) sold pursuant to that certain Subscription Agreement, dated September 22, 2023, filed as Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on September 13, 2023 (the “Form 8-K”); (ii) 2,000,000 shares of Common Stock of the Issuer (the “Warrant Shares”), issuable upon exercise of that certain Common Stock Warrant, in substantially the form as the form of warrant filed as Exhibit 4.1 to the Form 8-K (the “Warrant”), issued by the Issuer in favor of Nirland Limited, a company registered in Guernsey with company number 58804 of The Old Stables Rue a L’Or, St Peter Port, GUERNSEY GY1 1QG (“Nirland Limited”), which may be exercised at any time beginning thirty (30) days after the completion of the initial business combination (the “Business Combination”); and (iii) 2,520,311 shares of Common Stock purchased by Nirland Limited from St George Street Capital Limited, a limited liability company incorporated under the laws of the United Kingdom, pursuant to that certain share purchase agreement, dated as of September 22, 2023 (the “St George Purchase Agreement”).

     

    (2)Nirland Limited is wholly owned by Stockton Limited, a company registered in Guernsey (“Stockton Limited”), which is wholly owned by The Rowland Master Trust, a Guernsey trust (“The Rowland Master Trust”). Dovet Limited, a company registered in Guernsey (“Dovet Limited”), is the sole trustee of The Rowland Master Trust. By virtue of these relationships, each of Stockton Limited, The Rowland Master Trust and Dovet Limited may be deemed to share beneficial ownership of the securities held of record by Nirland Limited.

     

    (3)Such percentage is based on an aggregate of 74,418,316 shares of Common Stock outstanding, which is calculated by adding (i) 72,418,316 shares of Common Stock issued and outstanding as of September 22, 2023, as reported in the Issuers Form 8-K filed with the SEC on September 29, 2023, and (ii) 2,000,000 Warrant Shares issuable upon exercise of the Warrant.

    5

     

     

    Item 1.

     

    (a)Name of Issuer: Conduit Pharmaceuticals Inc. (formerly Murphy Canyon Acquisition Corp.)

     

    (b)Address of Issuer’s Principal Executive Offices: 4995 Murphy Canyon Road, Suite 300, San Diego, CA 92123

     

    Item 2.

     

    (a)Name of Person Filing:

     

    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):

     

    ●Nirland Limited, a company registered in Guernsey;

    ●Stockton Limited, a company registered in Guernsey;

    ●The Rowland Master Trust, a Guernsey trust; and

    ●Dovet Limited, a company registered in Guernsey.

     

    Stockton Limited is the sole owner of Nirland Limited, and as a result, may be deemed to share voting and dispositive power with respect to the securities held by Nirland Limited. The Rowland Master Trust is the sole owner of Stockton Limited, and as a result, may be deemed to share voting and dispositive power with respect to the securities held by Nirland Limited. Dovet Limited is the sole trustee of The Rowland Master Trust, and as a result, may be deemed to share voting and dispositive power with respect to the securities held by Nirland Limited.

     

    The Reporting Persons have entered into a Joint Filing Agreement, dated October 2, 2023, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which the Reporting Persons have agreed to file this statement and any subsequent amendments hereto jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act. Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed as an admission that any of the forgoing persons or the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the Common Stock reported herein.

     

    (b)Address of Principal Business Office or, if None, Residence: The address of the business office of each of the Reporting Persons is The Old Stables, Rue a l’Or, St Peter Port, GY1 1QG, Guernsey.

     

    (c)Citizenship: Each Reporting Person is registered in Guernsey.

     

    (d)Title and Class of Securities: Common stock, par value $0.0001 per share.

     

    (e)CUSIP No.: 20678X106

     

    6

     

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)☐ Broker or dealer registered under Section 15 of the Act;

     

    (b)☐ Bank as defined in Section 3(a)(6) of the Act;

     

    (c)☐ Insurance Company as defined in Section 3(a)(19) of the Act;

     

    (d)☐ Investment Company registered under Section 8 of the Investment Company Act;

     

    (e)☐ Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

    (f)☐ Employee benefit plan or endowment plan in accordance with Rule 13d-1(b)(1)(ii)(F);

     

    (g)☐ Parent holding company or control person, in accordance with Rule 13d-1(b)(1)(ii)(G);

     

    (h)☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

    (i)☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940;

     

    (j)☐ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

     

    (k)☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(j).
       
      ☒ If this statement is filed pursuant to Rule 13d-1(c), check this box.

     

    Item 4.Ownership

     

    (a)Amount Beneficially Owned: The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 5.Ownership of Five Percent or Less of a Class. N/A

     

    Item 6.Ownership of more than Five Percent on Behalf of Another Person. N/A

     

    Item 7.Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person. N/A

     

    Item 8.Identification and classification of members of the group. N/A

     

    Item 9.Notice of Dissolution of Group. N/A

     

    Item 10.Certifications.

     

    By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: October 2, 2023

     

      NIRLAND LIMITED
         
      By: /s/ David Rowland
      Name:   David Rowland
      Title: Director
         
      STOCKTON LIMITED
         
      By: /s/ David Rowland
      Name: David Rowland
      Title: Director
         
      THE ROWLAND MASTER TRUST
         
      By: Dovet Limited, its trustee
         
      By: /s/ Harley Rowland
      Name:  Harley Rowland
      Title: Director
         
      DOVET LIMITED
         
      By: /s/ Harley Rowland
      Name: Harley Rowland
      Title: Director

     

     

    78

     

     

    Get the next $MURF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MURF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MURF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination

    SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited ("Conduit Pharmaceuticals"), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., a special purpose acquisition company (NASDAQ:MURF) ("MURF"), announced today the completion of the previously announced business combination (the "Transaction"). Conduit expects to commence trading on September 25, 2023, under ticker symbol "CDT" for its common stock on The Nasdaq Global Market and ticker symbol "CDTTW" for its warrants on The Nasdaq Capital Market.At the debut of trading, there will be a pro forma enterpris

    9/22/23 9:01:00 AM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Murphy Canyon Acquisition Corp. Announces Stockholder Approval of the Proposed Combination with Conduit Pharmaceuticals Limited

    SAN DIEGO, CA / ACCESSWIRE / September 20, 2023 / Murphy Canyon Acquisition Corp. (NASDAQ:MURF) ("MURF" or "Murphy Canyon"), a special purpose acquisition company, announced today that at a special meeting of the MURF stockholders (the "Special Meeting") held today, MURF's stockholders voted in favor of the proposed business combination (the "Business Combination") with Conduit Pharmaceuticals Limited ("Conduit") and the related proposals. As a result, the completion of the Business Combination is expected to occur as soon as practicable, subject to the satisfaction or waiver of remaining closing conditions. Following the completion of the Business Combination, the newly combined company wil

    9/20/23 5:40:00 PM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Presidio Property Trust, Inc. Announces Establishment of a Special Committee of the Board and Exploration of Strategic Alternatives

    SAN DIEGO, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Presidio Property Trust, Inc. (NASDAQ:SQFT, SQFTP))) (the "Company"), an internally managed, diversified real estate investment trust ("REIT"), today announced that its Board of Directors (the "Board") has established a Special Committee of the Board (the "Special Committee") to explore potential strategic alternatives focusing on maximizing stockholder value. The Special Committee is comprised solely of independent directors and is charged with exploring potential strategic alternatives, including, without limitation, a business combination involving the Company, a sale of all or part of the Company's assets, joint venture arrangements and/or

    9/13/23 8:30:00 AM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    $MURF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lewis-Hall Freda C

    4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)

    12/14/23 5:16:03 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Mcnealey Jennifer Isacoff

    4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)

    12/5/23 5:20:25 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bligh James

    4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)

    12/5/23 5:20:29 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURF
    SEC Filings

    View All

    SEC Form S-8 filed by Murphy Canyon Acquisition Corp.

    S-8 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)

    1/10/24 4:43:04 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Murphy Canyon Acquisition Corp.

    424B3 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)

    12/18/23 4:14:52 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Murphy Canyon Acquisition Corp.

    EFFECT - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)

    12/18/23 12:15:16 AM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURF
    Financials

    Live finance-specific insights

    View All

    Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination

    SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited ("Conduit Pharmaceuticals"), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., a special purpose acquisition company (NASDAQ:MURF) ("MURF"), announced today the completion of the previously announced business combination (the "Transaction"). Conduit expects to commence trading on September 25, 2023, under ticker symbol "CDT" for its common stock on The Nasdaq Global Market and ticker symbol "CDTTW" for its warrants on The Nasdaq Capital Market.At the debut of trading, there will be a pro forma enterpris

    9/22/23 9:01:00 AM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Murphy Canyon Acquisition Corp. Announces Stockholder Approval of the Proposed Combination with Conduit Pharmaceuticals Limited

    SAN DIEGO, CA / ACCESSWIRE / September 20, 2023 / Murphy Canyon Acquisition Corp. (NASDAQ:MURF) ("MURF" or "Murphy Canyon"), a special purpose acquisition company, announced today that at a special meeting of the MURF stockholders (the "Special Meeting") held today, MURF's stockholders voted in favor of the proposed business combination (the "Business Combination") with Conduit Pharmaceuticals Limited ("Conduit") and the related proposals. As a result, the completion of the Business Combination is expected to occur as soon as practicable, subject to the satisfaction or waiver of remaining closing conditions. Following the completion of the Business Combination, the newly combined company wil

    9/20/23 5:40:00 PM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Presidio Property Trust, Inc. Announces Earnings for the Quarter Ended June 30, 2023

    SAN DIEGO, CA / ACCESSWIRE / August 14, 2023 / Presidio Property Trust, Inc. (NASDAQ:SQFT)(NASDAQ:SQFTP) (the "Company"), an internally managed, diversified real estate investment trust ("REIT"), today reported earnings for its quarter ended June 30, 2023.Quarter Ended June 30, 2023, Financial ResultsNet loss attributable to the Company's common stockholders for the three months ended June 30, 2023, was approximately $1,831,889, or $(0.15) per basic and diluted share, compared to a net loss of approximately $830,212, or $(0.07) per basic and diluted share for the three months ended June 30, 2022. The change in net income attributable to the Company's common stockholders was a result of: •An

    8/14/23 5:30:00 PM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    $MURF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    2/12/24 12:51:14 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    2/8/24 1:15:17 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    2/2/24 4:28:59 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care